Carles J, Domenech M, Gelabert-Mas A, Nogue M, Tabernero J M, Arcusa A, Guasch I, Miguel A, Ballesteros J J, Fabregat X
Uro-Oncology Unit, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Spain.
Acta Oncol. 1998;37(2):187-91. doi: 10.1080/028418698429757.
The purpose of this study was to evaluate the antitumor activity of vinorelbine and oral estramustine phosphate in patients with metastatic, hormone-refractory prostate cancer. We evaluated the activity of this association using the following schedule: estramustine phosphate 600 mg/m2/day orally days 1-42 and vinorelbine 25 mg/m1 days 1, 8, 22, 29 cycles repeated every 56 days. Twenty-five patients were included in the study, 24 being evaluable for response and 25 for toxicity. Out of 5 patients with measurable disease, none had an objective response. Of the 24 assessable patients with bone metastases, 9 patients had a > or = 65% decline in pretreatment prostate-specific antigen (PSA) level, stable disease was observed in 10 and 5 patients progressed. Toxicities were minimal. Anemia was observed in 5 patients, alopecia in 4 and nausea and vomiting was observed in 6 patients. Anorexia and weight loss of more than 10% were observed in 2 patients. This combination is active and well tolerated in hormone-resistant prostate cancer. These results support the therapeutic strategy of combining agents that impair microtubule function.
本研究的目的是评估长春瑞滨和口服磷酸雌莫司汀对转移性激素难治性前列腺癌患者的抗肿瘤活性。我们采用以下方案评估了这种联合用药的活性：磷酸雌莫司汀600mg/m²/天，口服，第1 - 42天；长春瑞滨25mg/m²，于第1、8、22、29天给药，每56天重复一个周期。25例患者纳入本研究，其中24例可评估疗效，25例可评估毒性。5例有可测量病灶的患者中，无客观缓解。24例可评估的骨转移患者中，9例患者治疗前前列腺特异性抗原（PSA）水平下降≥65%，10例病情稳定，5例进展。毒性反应轻微。5例患者出现贫血，4例出现脱发，6例出现恶心和呕吐。2例患者出现厌食和体重减轻超过10%。这种联合用药在激素抵抗性前列腺癌中具有活性且耐受性良好。这些结果支持联合使用损害微管功能药物的治疗策略。
